Is Recursion Pharmaceuticals Stock a Buy?
Amidst the artificial intelligence (AI) revolution and a rapidly shifting landscape in drug development, Recursion Pharmaceuticals (NASDAQ: RXRX) is aiming to position itself at the intersection of both big trends. While it isn't the only biotech exploring these rising opportunities, it just might be one of the few to have what's needed to succeed in such a dynamic time.
Still, innovative businesses also tend to be risky investments. Does this company have what it takes to overcome the risk and reward investors buying today? Let's evaluate what the bulls and bears are saying About Recursion Pharmaceuticals.
The core problem Recursion seeks to solve is that the process of discovering and making new medicines is becoming slower and more costly over time, despite perpetually increasing knowledge of human biology and ever more sophisticated approaches to the research and development (R&D) process.
Source Fool.com
